H.C. Wainwright lowered the firm’s price target on Annovis Bio to $30 from $40 and keeps a Buy rating on the shares. The analyst says the company’s equity financing transaction facilitates clinical advancement.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ANVS:
